Nuclear receptor corepressor 2 mRNA 3′ untranslated region (NCOR2 mRNA 3′ UTR)

The Nuclear receptor corepressor 2 mRNA 3′ untranslated region (NCOR2 mRNA 3′ UTR) is a critical regulatory segment of the NCOR2 transcript that governs the stability and translation of the NCOR2 protein [1]. NCOR2, also known as SMRT (Silencing Mediator for Retinoid and Thyroid hormone receptors), acts as a transcriptional corepressor for various nuclear receptors and transcription factors, playing a vital role in gene silencing and metabolic homeostasis [2]. The 3′ UTR contains multiple binding sites for microRNAs, such as miR-16 and miR-181, and RNA-binding proteins, which modulate NCOR2 expression levels in response to cellular signals [3]. Dysregulation of NCOR2 expression, often mediated through its 3′ UTR, is implicated in the progression of several cancers, including prostate and breast cancer, as well as metabolic diseases like type 2 diabetes [4]. Therapeutic strategies targeting this region involve the use of antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) to either degrade the transcript or block microRNA binding, thereby restoring normal NCOR2 levels [5]. While no drugs targeting the NCOR2 3′ UTR are currently FDA-approved, it remains a significant area of interest for precision medicine and RNA-targeted therapies [6]. This target is particularly relevant in oncology, where restoring corepressor function can inhibit aberrant transcriptional programs driving tumor growth [7]. (Sources: [1] NCBI Gene ID: 9612; [2] UniProt P42701; [3] PubMed PMID: 30333318; [4] Nature Reviews Endocrinology 2013, 9(7):407-420; [5] Molecular Therapy 2021; [6] ClinicalTrials.gov; [7] Cancer Research 2018).

Other names

SMRT mRNA 3′ UTRSilencing mediator for retinoid and thyroid hormone receptors mRNA 3′ UTRNCOR2 3′-UTRNuclear receptor corepressor 2 3′-untranslated region

Modulation of NCOR2 protein expression through sequence-specific binding to the 3′ untranslated region, leading to mRNA degradation via RNase H recruitment or translational inhibition by blocking microRNA binding sites.